Calculate safe hydroxychloroquine (Plaquenil) dosing by actual and ideal body weight with retinal toxicity risk assessment per AAO guidelines.
Hydroxychloroquine (HCQ, brand name Plaquenil) is a cornerstone therapy for systemic lupus erythematosus (SLE) and rheumatoid arthritis, with proven benefits in reducing disease flares, organ damage, and mortality. However, long-term use carries a significant risk of irreversible retinal toxicity (hydroxychloroquine retinopathy) that is directly related to cumulative dose and daily dose relative to body weight. The American Academy of Ophthalmology (AAO) 2016 revised guidelines established that the maximum safe dose should not exceed 5 mg/kg of actual body weight per day, replacing the older recommendation of ≤ 6.5 mg/kg of ideal body weight.
This calculator determines the maximum safe hydroxychloroquine dose based on the patient's actual body weight, computes ideal body weight using the Devine formula for comparison, generates a retinal toxicity risk assessment based on five key factors (dose, duration, renal function, tamoxifen co-use, and pre-existing macular disease), and provides the current AAO ophthalmologic screening schedule. For patients whose calculated maximum dose falls between the available 200 mg tablet sizes, it suggests alternating-day dosing schedules.
Understanding hydroxychloroquine dosing is critical because retinal toxicity prevalence increases dramatically after 5 years of use — from less than 1% in the first 5 years to up to 20% after 20 years at doses exceeding 5 mg/kg/day. Once hydroxychloroquine retinopathy is detected, it is irreversible and may progress even after drug discontinuation, making prevention through proper dosing the primary strategy.
Hydroxychloroquine retinopathy is irreversible, making correct dosing the primary prevention strategy. This calculator ensures doses stay within the AAO-recommended ≤ 5 mg/kg/day limit, calculates ideal body weight for comparison, assesses cumulative retinal toxicity risk across five factors, and provides the appropriate ophthalmologic screening schedule — critical information often overlooked in routine prescribing.
Maximum safe dose = actual body weight (kg) × 5 mg/kg/day. Ideal body weight (Devine): Males = 50 + 2.3 × (height in inches - 60). Females = 45.5 + 2.3 × (height in inches - 60). Cumulative dose (g) = daily dose (mg) × 365 × years ÷ 1,000.
Result: Max safe dose: 300 mg/day (5 × 60 kg). Recommend 200 mg + alternating 400/200 schedule.
A 60 kg female: max = 300 mg/day. Since 200 mg tablets are the only formulation, an alternating schedule of 400 mg some days and 200 mg others achieves ~300 mg/day average. At 7 years, annual ophthalmologic screening is recommended.
The 2016 American Academy of Ophthalmology guidelines made several important changes to hydroxychloroquine screening and dosing recommendations. The maximum daily dose was reduced from 6.5 mg/kg of ideal body weight to 5 mg/kg of actual body weight, reflecting newer data showing that retinal toxicity risk is better predicted by actual weight-based dosing. The use of multifocal ERG was deemphasized in favor of spectral-domain OCT as the primary screening tool, with 10-2 visual field testing as a complementary modality. The recommendation for baseline eye exam within the first year was maintained, with annual screening starting after 5 years for low-risk patients.
Hydroxychloroquine accumulates in the retinal pigment epithelium (RPE) and is slowly released over months to years, even after drug discontinuation. The exact mechanism involves inhibition of lysosomal function in RPE cells, accumulation of lipofuscin-like material, and eventual photoreceptor cell death. The characteristic "bull's eye" maculopathy pattern results from this parafoveal photoreceptor loss. Asian patients may present with a more peripheral distribution of retinal damage, making standard 10-2 visual field testing less sensitive — wider field testing (24-2 or 30-2) may be warranted.
Despite retinal toxicity concerns, the overall benefit-risk ratio of hydroxychloroquine in SLE is strongly positive. HCQ reduces lupus flares by 50%, decreases organ damage accrual, improves survival, reduces thrombotic risk, has favorable effects on lipid profiles, and lowers the risk of neonatal lupus and congenital heart block in pregnancies. Current EULAR guidelines recommend hydroxychloroquine for all SLE patients unless contraindicated, reinforcing the importance of proper dosing to allow long-term safe use.
Per the AAO 2016 guidelines, the maximum safe dose is ≤ 5 mg/kg of actual body weight per day. For most patients, this means ≤ 400 mg/day. The previous guideline of 6.5 mg/kg of ideal body weight has been superseded.
The AAO 2016 guidelines recommend using actual body weight. However, in obese patients, the drug does not distribute proportionally into fat tissue, so some clinicians use the lesser of actual weight or ideal body weight × 1.2 as a conservative approach.
HCQ retinopathy is damage to the retinal pigment epithelium and photoreceptors, typically in a "bull's eye" pattern around the macula. It is irreversible and can progress after stopping the drug. Early detection by OCT is critical because advanced retinopathy causes permanent central vision loss.
Per AAO guidelines: baseline exam within the first year, then annual screening after 5 years of use. Patients with risk factors (renal disease, high dose, macular disease) should begin annual screening sooner. Screening includes OCT and 10-2 visual field testing.
Hydroxychloroquine is partially cleared by the kidneys. Decreased renal function leads to drug accumulation, increasing retinal toxicity risk. Patients with significant renal impairment may need dose reduction and should begin ophthalmologic screening earlier than the standard 5-year mark.
Yes. Unlike many immunosuppressants, hydroxychloroquine is considered safe during pregnancy and breastfeeding. It is actually recommended to continue HCQ throughout pregnancy in SLE patients, as discontinuation increases flare risk and adverse pregnancy outcomes.